中国药业2016，Vol.25Issue(9)：15-17,18,4.
宫颈癌患者外周血ERCC1基因多态性对顺铂新辅助化疗疗效的影响
Influence of Peripheral Blood ERCC1 Gere Polymorphism on Patients with Cervical Cancer Undergoing Neoadjuvant Cisplatin Chemotherapy
摘要
Abstract
Objective To investigate the influence of peripheral blood ERCC1 gene polymorphism on patients with cervical cancer under-going neoadjuvant cisplatin chemotherapy. Methods 80 cases with cervical cancer from March 2010 to June 2014 were divided into CC group and TT group according to the ERCC1 gene expression of the peripheral blood, 40 cases in each group. The two groups were given paclitaxel combined with cisplatin chemotherapy, 21 d for 1 course, altogether 6 courses. At the end of the treatment, the short-term efficacy of the two groups were compared, and the median survival, the median time to progression, the two years survival rate were compared between the two groups, and the occurrence of adverse reactions was recorded. Results After treatment, the short-term effica-cy of the TT group was 52. 50%, the short-term efficacy of CC group was 67. 50%, CC group was significantly better than that in control group ( P < 0. 05 );the median progression, median survival and 2-year survival rate were significantly higher than those in TT group ( P < 0. 05 ) . After treatment, serum CYFRA21-1, SCC-Ag expressions in the two groups were decreased, and the level of CC was significantly higher than that of TT group, the difference was statistically significant ( P < 0. 05 ) . The incidence of adverse reactions in two groups were observed, and the results showed no significant difference ( P > 0. 05 ) . Conclusion The clinical efficacy of C19007T ERCC1 in patients with C/C was better than that of patients with T/T. The median time to progression, median survival and two years survival were higher. The expression of specific tumor markers in serum was significantly lower, and the incidence rate of adverse reac-tions was similar.关键词
核苷酸切除修复交叉互补1/C19007T/基因多态性/宫颈癌/临床疗效Key words
ERCC1/C19007T/gene polymorphism/cervical cancer/clinical efficacy分类
医药卫生引用本文复制引用
关灵,郑锐年,吴少敏,林顺欢,李仲均,吴依芬,廖玉婷,江丽华,赵燕海..宫颈癌患者外周血ERCC1基因多态性对顺铂新辅助化疗疗效的影响[J].中国药业,2016,25(9):15-17,18,4.基金项目
广东省东莞市科技计划医疗卫生类科研一般项目，项目编号2015105101180。 （）
